Terms: = Lymphoma AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Prognosis
78 results:
1. [Interim results of a multicenter cohort study for Chinese Children Leukemia Group-acute lymphoblastic leukemia 2018 regimen].
Chinese Children Leukemia Group
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):874-880. PubMed ID: 37803853
[No Abstract] [Full Text] [Related]
2. Apoptosis-mediated inhibition of human T-cell acute lymphoblastic leukemia upon treatment with
Duarte A; Montagna DR; Pastorini M; Alemán M
Front Immunol; 2023; 14():1176432. PubMed ID: 37377961
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase.
Gao T; Huang J; Yin H; Huang J; Xie J; Zhou T; Fan W; Yang X; Gao G; Li Z
Cell Death Dis; 2023 May; 14(5):316. PubMed ID: 37160920
[TBL] [Abstract] [Full Text] [Related]
4. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
6. Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal lymphoma With Methotrexate.
Gu J; Jiang T; Liu S; Chen X; Wang Z; Zhang P; Wang L; Jiang R; Huang X; Xu G; Chang Q
Am J Ophthalmol; 2023 Jul; 251():189-196. PubMed ID: 36963600
[TBL] [Abstract] [Full Text] [Related]
7. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies.
Hernández-Molina G; Kostov B; Brito-Zerón P; Vissink A; Mandl T; Hinrichs AC; Quartuccio L; Baldini C; Seror R; Szántó A; Isenberg D; Gerli R; Nordmark G; Rasmussen A; Solans-Laque R; Hofauer B; Sène D; Pasoto SG; Rischmueller M; Praprotnik S; Gheita TA; Danda D; Armağan B; Suzuki Y; Valim V; Devauchelle-Pensec V; Retamozo S; Kvarnstrom M; Sebastian A; Atzeni F; Giacomelli R; Carsons SE; Kwok SK; Nakamura H; Fernandes Moça Trevisani V; Flores-Chávez A; Mariette X; Ramos-Casals M;
Rheumatology (Oxford); 2022 Dec; 62(1):243-255. PubMed ID: 35385104
[TBL] [Abstract] [Full Text] [Related]
8. [Relationships between CASP8, fas Gene Polymorphisms and the prognosis of Patients with Non-Hodgkin's lymphoma in Han Nationality].
Huang Y; Hu S; Cui WT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1493-1497. PubMed ID: 34627429
[TBL] [Abstract] [Full Text] [Related]
9. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
López-Nevado M; González-Granado LI; Ruiz-García R; Pleguezuelo D; Cabrera-Marante O; Salmón N; Blanco-Lobo P; Domínguez-Pinilla N; Rodríguez-Pena R; Sebastián E; Cruz-Rojo J; Olbrich P; Ruiz-Contreras J; Paz-Artal E; Neth O; Allende LM
Front Immunol; 2021; 12():671755. PubMed ID: 34447369
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D; Sanches JA
Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
[TBL] [Abstract] [Full Text] [Related]
11. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.
Gámez-Díaz L; Grimbacher B
Biomed J; 2021 Aug; 44(4):400-411. PubMed ID: 34384744
[TBL] [Abstract] [Full Text] [Related]
12. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).
Casamayor-Polo L; López-Nevado M; Paz-Artal E; Anel A; Rieux-Laucat F; Allende LM
Crit Rev Clin Lab Sci; 2021 Jun; 58(4):253-274. PubMed ID: 33356695
[TBL] [Abstract] [Full Text] [Related]
13. MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of fasL in M1 macrophages.
Lou X; Fu J; Zhao X; Zhuansun X; Rong C; Sun M; Niu H; Wu L; Zhang Y; An L; Guo L; Wan S; Wang S
J Exp Clin Cancer Res; 2020 Nov; 39(1):237. PubMed ID: 33168041
[TBL] [Abstract] [Full Text] [Related]
14. The Inhibitor of Apoptosis Protein Livin Confers Resistance to fas-Mediated Immune Cytotoxicity in Refractory lymphoma.
Sugihara E; Hashimoto N; Osuka S; Shimizu T; Ueno S; Okazaki S; Yaguchi T; Kawakami Y; Kosaki K; Sato TA; Okamoto S; Saya H
Cancer Res; 2020 Oct; 80(20):4439-4450. PubMed ID: 32928920
[TBL] [Abstract] [Full Text] [Related]
15. Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell lymphoma: A Single-Arm, Open-Label, Phase II Trial.
Mei Q; Zhang W; Liu Y; Yang Q; Rasko JEJ; Nie J; Liu J; Li X; Dong L; Chen M; Zhang Y; Shi L; Wu H; Han W
Clin Cancer Res; 2020 Sep; 26(17):4521-4530. PubMed ID: 32499235
[TBL] [Abstract] [Full Text] [Related]
16. Survival of Patients With Second Primary Hodgkin lymphoma.
Budnik J; Doucette C; Milano MT; Constine LS
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):316-323.e2. PubMed ID: 32014390
[TBL] [Abstract] [Full Text] [Related]
17. Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells.
Chi Z; Gao H; Liu H; Wu B; Zhang B; Gu M; Yang W
Mol Med Rep; 2020 Feb; 21(2):936-944. PubMed ID: 31974619
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
[TBL] [Abstract] [Full Text] [Related]
19. [Expression of mTOR and 4E-BP1 in extranodal Nasal-type NK/T-cell lymphoma and implication for prognosis].
Zhang Q; Liu G; Hang W
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 33(2):123-127. PubMed ID: 30808136
[No Abstract] [Full Text] [Related]
20. S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.
Marín-Rubio JL; Pérez-Gómez E; Fernández-Piqueras J; Villa-Morales M
Carcinogenesis; 2019 Oct; 40(10):1260-1268. PubMed ID: 30805584
[TBL] [Abstract] [Full Text] [Related]
[Next]
